Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1997-07-11
2000-10-03
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 111, 424 157, 424 165, 424 91, 424 93, 530300, 530317, 530324, 530333, 530334, 530335, 530336, 530337, 530338, 534 10, 534 14, A61K 5100, A61K 4900, A61M 3614, A61B 5055
Patent
active
061269166
ABSTRACT:
Novel metal binding ligands are disclosed that may be coupled to peptides for use in methods of diagnosis and therapy. Peptides containing the ligands are produced using a method wherein ligand introduction or cyclization can be conducted at any point during the synthesis of the peptide. Such peptide derivatives are readily labeled with radiometals, such as isotopes of rhenium or technetium, while retaining their ability to tightly bind specific peptide receptors.
REFERENCES:
patent: 4564472 (1986-01-01), Ueda et al.
patent: 4822890 (1989-04-01), Bolin
patent: 5080884 (1992-01-01), McBride et al.
patent: 5225180 (1993-07-01), Dean et al.
patent: 5227474 (1993-07-01), Johnson et al.
patent: 5449761 (1995-09-01), Belinka, Jr. et al.
patent: 5753206 (1998-05-01), McBride et al.
Virgolini et al., "Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors" The New England Journal of Medicine pp. 1116-1121 (1994).
Virgolini et al., "Vasoactive Intestinal Peptide Receptor Scintigraphy" The Journal of Nuclear Medicine 36:1732-1739 (1995).
Lister-Jamcs et al., "Radiopharmaceutical Chemistry: Protein, Peptides, Antibodies I" No. 370 36:91P (1995).
Pearson et al., "Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m: Chemistry and Initial Biological Studies" J. Med. Chem. 39:1361-1371 (1996).
Krenning et al., "Somaostatin Receptor Scintigraphy with Indium-111-DPTA-D-Phe-1-Octreotide in Man: Metabolism, Dosimetry and Comparison with Iodine-123-TYr-3-Octreotide" The Journal of Nuclear Medicine.
Wraight et al., "The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of melanoma" The British Journal of Radiology 65:112-118 (1992).
Reubi, "In Vitro Identification of Vasoactive Intestinal Peptide Receptors in Human Tumors: Implications for Tumor Imaging" The Journal of Nuclear Medicine 36:1846-1853 (1995).
Maina et al., "Synthesis, Radiochemical and Biological Evaluation of .sup.99m Tc[N4(D)Phe.sup.1 ]-Octreotide, a New Octreotide Derivative with High Affinity for Somatostatin Receptor" The Journal of Nuclear Biology and.
Bajusz et al., "Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone" Proc. Natl. Acad. Sci. USA 86:6313-6317 (1989).
Felix et al., "Synthesis, biological activity and conformational analysis of cyclic GRF analogs" J. Peptide Protein Res. 32:441-454 (1988).
Edwards et al., "Generally Applicable, Convenient Solid-Phase Synthesis and Receptor Affinities of Octreotide Analogs" J. Med. Chem. 37:3749-3757 (1994).
Bienstock et al., "Conformational Analysis of a Highly Potent Dicyclic Gonadotropin-Releasing Hormone Antagonist by Nuclear Magnetic Resonance and Molecular Dynamics" American Chemical Society pp. 3265-.
Barbacci et al., "The Structural Basis for the Specificity of Epidermal Growth Factor and Heregulin Binding" The Journal of Biological Chemistry 270:9585-9589 (1995).
Haskell-Luevano et al., "Characterizations of the Unusual Dissociation Properties of Melanotropin Peptides from the Melanocortin Receptor, hMC1R" J. Med. Chem. 39:432-435 (1996).
Al-Obeidi et al., "Design of a New Class of Superpotent Cyclic .alpha.-Melanotropins Based on Quenched Dynamic Simulations" J. AM. Chem. Soc. 111:3413-3416 (1989).
O'Donnell et al., "Ro 25-1553: A Novel, Long-Acting Vasoactive Intestinal Peptide Agonist. Part I: In Vitro and In Vivo Bronchodilator Studies" The Journal of Pharmacology and Experimental Therapeutics 270:1282-1294.
Virgolini et al., "Cross-Competition between Vasoactive Intestinal Peptide and Somatostatin for Binding to Tumor Cell Membrane Receptors.sup.1 " Cancer Research pp. 690-700 (1994).
Griffiths Gary L.
McBride William J.
Garcia Maurie E.
Immunomedics Inc.
MacMillan Keith D.
LandOfFree
Radiometal-binding peptide analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radiometal-binding peptide analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiometal-binding peptide analogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-192195